DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.35

Change

-0.04 (-0.48)%

Market Cap

USD 0.17B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-0.36 (-0.34%)

USD 17.87B
IVV:AU iShares Core S&P 500 AUD

-0.24 (-0.37%)

USD 11.24B
VGS:AU Vanguard MSCI International Sh..

-0.48 (-0.34%)

USD 10.01B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.31 (-0.52%)

USD 7.10B
IOZ:AU Ishares Core S&P/Asx 200

-0.13 (-0.38%)

USD 6.40B
STW:AU SPDR® S&P/ASX 200 Fund

-0.30 (-0.39%)

USD 5.57B
VTS:AU Vanguard US Total Market Share..

-1.63 (-0.34%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-0.27 (-0.52%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.33 (-0.75%)

USD 4.86B
A200:AU BetaShares Australia 200

-0.56 (-0.40%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.23% 92% A 70% C-
Dividend Return 0.35% 11% F 9% A-
Total Return 6.58% 92% A 71% C-
Trailing 12 Months  
Capital Gain -0.36% 11% F 50% F
Dividend Return 2.99% 41% F 33% F
Total Return 2.63% 12% F 50% F
Trailing 5 Years  
Capital Gain 22.25% 68% D+ 72% C
Dividend Return 10.71% 25% F 26% F
Total Return 32.97% 54% F 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.84% 64% D 55% F
Dividend Return 8.56% 63% D 54% F
Total Return 1.72% 58% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 8.49% 65% D 92% A
Risk Adjusted Return 100.85% 90% A- 96% N/A
Market Capitalization 0.17B 33% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.